Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Continued benefit seen with 4-year odanacatib therapy in postmenopausal women

Oct. 22, 2010

Phase II trials assess Amgen's antibodies in pancreatic and non-small cell lung cancer

Oct. 22, 2010

Oncolytic vaccinia virus GL-ONC1 well tolerated in patients with solid cancers

Oct. 22, 2010

Phase I trial evaluates MVA-BN PRO in castration-resistant prostate cancer

Oct. 21, 2010

ONO-4641 shows safety and tolerability in phase I trial in MS

Oct. 21, 2010

Subanalyses of CLARITY data support benefits of cladribine tablets

Oct. 21, 2010

Zealand Pharma's ZP-2307 shows bone anabolic activity in vivo

Oct. 21, 2010

New antibiotics for multidrug-resistant pathogens in preclinical/clinical evaluation

Oct. 21, 2010

Ocrelizumab reduces disease activity in phase II trial in relapsing-remitting MS

Oct. 20, 2010

DepoVax-based vaccination leads to tumor regression in vivo

Oct. 20, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...